Canada markets closed

Clearside Biomedical, Inc. (CLSD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1900-0.0400 (-3.25%)
At close: 04:00PM EDT

Clearside Biomedical, Inc.

900 North Point Parkway
Suite 200
Alpharetta, GA 30005
United States
678 270 3631

Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.President, CEO & Director836.15kN/A1952
Mr. Charles A. DeignanChief Financial Officer568.68kN/A1964
Dr. Thomas A. Ciulla M.B.A., M.D.Chairman of Scientific Advisory Board531.52kN/A1965
Ms. Jenny R. KobinHead of Investor RelationsN/AN/A1967
Mr. Rick McElhenySenior Vice President of Corporate Development & Alliance ManagementN/AN/AN/A
Mr. Rafael V. AndinoSenior Vice President of Engineering & ManufacturingN/AN/A1965
Ms. Susan L. Coultas Ph.D.Chief Clinical OfficerN/AN/AN/A
Dr. Ngai Hang Chong FRCOphth, M.D.Chief Medical OfficerN/AN/AN/A
Mr. Leslie B. ZacksSecretaryN/AN/A1969
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Corporate Governance

Clearside Biomedical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.